Upload
miki303
View
216
Download
0
Embed Size (px)
Citation preview
7/24/2019 140717 Committee Report
1/82
26 7 17
7/24/2019 140717 Committee Report
2/82
1
................................................................ - 1 -
................................................................... - 1 -
I.
......................................................................... - 2 -II.
......................................................................... - 2 -III.
......................................................................... - 3 -IV.
......................................................................... - 3 -V.
1. .................................... - 3 -
2. .................................... - 3 -
3. ...................................... - 4 -
4.
.................................... - 4 -
5. .............................. - 5 -
6. ................................................ - 5 -
7. ........................................................ - 5 -
(1)
Tissue ................................................................. - 5 -
(2) .................................................. - 6 -
(3) .................................................................... - 6 -
(4) .................................................................... - 6 -
(5) ............................................ - 6 -
(6) .............. - 6 -
(7) .............................................................. - 6 -
(8) .................................................... - 7 -
2
.......................................................... - 8 -
....................................................................... - 8 -I.
....................................... - 10 -II.
1. ............................................................. - 10 -
(1) ..................... - 10 -
(2) ................................................... - 21 -
(3) ............................................... - 22 -
(4)
Tissue ..................................... - 24 -
(5) ................................................. - 28 -
(6) ......................................................... - 28 -
2. ....................................................... - 29 -
(1) ............................... - 29 -
(2)
Tissue ....... - 32 -
(3) ......... - 34 -
7/24/2019 140717 Committee Report
3/82
(4) ......................................... - 45 -
- 47 -III.
1. ........................................... - 47 -
2.
....................................................... - 47 -
(1) 23 1........................................ - 47 -
(2) 23 1.............. - 47 -
(3) (1)............................... - 48 -
(4) (2).... - 50 -
3. .......................................................................... - 55 -
................................... - 56 -IV.
1. ................................. - 56 -
(1)
....................................................... - 56 -
(2) ................................................................. - 56 -
2. ..................................................... - 56 -
3. ................................................. - 57 -
(1) ..................................................... - 57 -
(2) ......................... - 62 -
4. .......................................................................... - 63 -
....................... - 64 -V.
1. ......................... - 64 -
(1) ........................................................... - 64 -
(2) ............................................................... - 64 -
(3) ............................................................... - 64 -
2. ..................................................... - 66 -
(1) ....................................................... - 66 -
(2) ....................................................... - 66 -
(3) ......................................... - 66 -
(4) ........................................... - 68 -
3. ........................... - 69 -
(1) ..................................................... - 69 -
(2) ..................................................... - 71 -
(3) ......................................... - 73 -
(4) ................................... - 74 -
(5) ......... - 74 -
4. .......................................................................... - 77 -
............................................................................ - 78 -VI.
7/24/2019 140717 Committee Report
4/82
- 1 -
1
.
26 2
First Author Nature STAP1
22Nature
First Author
Tissue EngineeringPart A3Tissue
4Tissue Tissue
5
26 2 21 26 3 15
26 3 15 A
1 Stimulus-triggered acquisition of pluripotency 2 Stimulus-triggered fate conversion of somatic cells into pluripotency 26
Bidirectional developmental potential in reprogrammed cells with acquired pluripotency
263 Mary Ann Liebert, Inc.,Tissue Engineering
1 24 4.065
(accept)
4 2 4 Haruko Obokata, et.al, The Potential of
Stem Cells in Adult Tissues Representative of the Three Germ Layers(TISSUE ENGINEERING: Part
A, Volume 17, Numbers 5 and 6) 23)5 Isolation of pluripotent adult stem cells discovered from tissues derived from all
three germ layers 23
7/24/2019 140717 Committee Report
5/82
- 2 -
26 3 17
26 3 28
31
26 3 31.
I.
II.
7/24/2019 140717 Committee Report
6/82
- 3 -
V.
26 3 31 7 16
.
.
Nature Tissue
1.
1)
26 4
24 5 29 2
6 26 4 30 5
28 6 11
2)
3)
26 6 22
4) 26 6 27
B
2.
1)
26 4 16 6
19
2)
26 4 11 5
20 23 2 9
6 C
7/24/2019 140717 Committee Report
7/82
- 4 -
DE
FGHIJK L
3)
26 5 2
M
4)
26 5 21
6 3 23 2 25
NA O
5)
26 6 18
23
1 11
P
6)
3.
1)
26 5 21
Q
2)
R
4.
1)
26 5 8
S
2)
T
7/24/2019 140717 Committee Report
8/82
- 5 -
5.
1)
26 5 9 5 23 2
CDB
U
2)
U
3) 26 4
24 6 207
26 5 8 6 25
6.
National Institutes of HealthNIHW
XZen-Bio, Inc.Zen-Bio
Harlan
7.
1)
Tissue
2 4 Tissue
Tissue
Tissue
7 V
7/24/2019 140717 Committee Report
9/82
- 6 -
2)
3)
U
4)
U
5)
.2.(3).c.(c)
.2.(3).c.(a)
6)
7) .2. 3)a.
7/24/2019 140717 Committee Report
10/82
- 7 -
8)
7/24/2019 140717 Committee Report
11/82
- 8 -
2
.
V.
20
4 1
5
9 1
6
21
1
3
4 1 2
8
22
6 30 Tissue Tissue
First Author
SRQ 1
Corresponding AuthorT
8 U
9 30 Tissue Tissue
11 11
11 13
11 17
12 8
R T 23
1 11
2 8
2 9
2 25
3 15
4 CDB
25
3 10 Nature Nature
7/24/2019 140717 Committee Report
12/82
- 9 -
12 20 Nature Nature
26
2 Nature
3 31
7/24/2019 140717 Committee Report
13/82
- 10 -
I.
1.
1)
8
910
a.
1 1 1.1 1.5 6
(a)
i.
11
8 45 5 6 48 21
2 1 15
2 1 1
2
9
10
6
6
11 NIH NIH
NIH
7/24/2019 140717 Committee Report
14/82
- 11 -
ii.
iii.
12
iv. NIH
v. 32
13
NIH21
(b)
.1.(1)a.(a)
i.
ii.
1
105NIH
2574 3
642512 13
32 1
35
35
7/24/2019 140717 Committee Report
15/82
- 12 -
4500
1 80 20 80
b. 25 Fig. 1
(a)
i.
ii.
14
iii.
iv. WW
v.
32
W21
(b)
.1.(1)b.(a)
i.
14 C-kit positive stem cells
7/24/2019 140717 Committee Report
16/82
- 13 -
ii.
c.
26 Fig. 2
1
1
(a)
1
i.
ii. 1
1
1
1516
iii.
1
1
1
15
14 6 28 55 4 837
16 1
1
21
7/24/2019 140717 Committee Report
17/82
- 14 -
iv.
XX
v. 32
1
X21
(b)
1.1.(1)c.(a)
i. 1
ii.
1
1
d.
71 Fig. 15 2
2
(a)
2
i.
ii. 2 2
iii. 2
2
2
7/24/2019 140717 Committee Report
18/82
- 15 -
iv.
XX
v. 32
2
X21
(b)
2.1.(1)d.(a)
i. 2
ii.
2
2
e.
73 Fig. 17 3
3
(a)
3
i.
ii. 3 3
iii. 3
3
3
7/24/2019 140717 Committee Report
19/82
- 16 -
iv.
XX
v. 32
3
X21
(b)
3.1.(1)e.(a)
i. 3
ii.
3
3
f.
46 2 2.6References 24 3158
3
3.6
References
76
4
4.6
References
1 49 93 5 5.6References
(a)
i.
17
17 12 1
7/24/2019 140717 Committee Report
20/82
- 17 -
ii.
iii.
iv.
v.
32
21
3 5
(b)
.1.(1)f.(a)
i.
ii.
7/24/2019 140717 Committee Report
21/82
- 18 -
3 5
g. 53 Fig. 10
18
(a)
i. Muscle
(i)
1 1
1 1
(ii) 1
1
(iii) 1
1
(iv) Zen-Bio
1 Zen-Bio
1
19
(v)
32
18
19
Zen-Bio
1
1
7/24/2019 140717 Committee Report
22/82
- 19 -
Zen-Bio 1 21
ii. hepatocyte
(i)
2 2
2
2
(ii)
2
2
(iii) 2
2
(iv)
2
2
(v) 32
2
21
(b)
.1.(1)g.(a)
i.
ii.
1 2
7/24/2019 140717 Committee Report
23/82
- 20 -
2021(c)
in vitro6
.2.(3)
.2.(3)f.(b)
h. 86 Fig. 20
(a)
i.
20
21
6
7/24/2019 140717 Committee Report
24/82
- 21 -
ii.
iii.
iv. HarlanHarlan
v. 32
Harlan 21
(b)
.1.(1)h.(a)
i.
ii.
2)
a.
42
Fig. 7
2Oct4/DAPI
SSEA-1/DAPIFigure 7 Pluripotent marker
expressions/Spheres at day 5 expressed pluripotent cell markers Oct4 and
SSEA-1. 2
7/24/2019 140717 Committee Report
25/82
- 22 -
22
b.
57
Fig. 14
3
3Figure 14 Teratoma like mass from
bone marrow spheres contained nerve expressing betaIII-tubuline
(left)(ectoderm), muscle expressing desmin (middle)(mesoderm) and duct like
structure expressing AFP (right)(endoderm).
3)
a. 28 2 2.2.1 11B. Optimistic pressure
13destroy mature cells.
3
A. Cell sorterB. Optimistic pressureC. Trituration
using thin-glass pipetteB. Optimistic
pressure
B. Optimistic pressure
Optimistic pressure
2324
b. 30 2 2.3.2only small
cells.
22 Fig. 7 Fig. 6 GFig. 7 Fig. 8
Oct4 Fig. 723 optimistic pressureosmotic pressure
24 Optimistic pressureOsmotic pressure
B. Osmotic pressure
2
2.2.1
7/24/2019 140717 Committee Report
26/82
- 23 -
Fig. 3
c. 33 2 2.3.6three germ
layers was examined.
Fig. 8
25
d. 36 2 2.5The mechanisms or process to
express pluripotent cell markers in spheres may be distinct from ES
cells or iPS cells.
iPS
iPS
e.
68 4 4.3.3 3Neural cells ectoderm
lineage)
13
CK18 Fig. 17x - A,B,C) was seen.
in vitro
Fig. 17i
- A,B,CFig. 17
Fig. 17
25 1 4 4.3.2662
7/24/2019 140717 Committee Report
27/82
- 24 -
4)
Tissue
a.
54 Fig. 11 3
3 3.3.1 4 6The addition(a)
of 14into endodermal tissue.
Tissue
611 11 3The addition of 11
into endodermal tissue.
Fig. 4
Tissue(b)
Ectoderm Tissue26
Tissue
Mesoderm Tissue27(c)
Tissue
Endoderm Tissue28(d)
Tissue
Tissue
Tissue
Tissue
b. 73 Fig. 17 27
26 Fig. 4 B27 Fig. 4 E28 Fig. 4 H
7/24/2019 140717 Committee Report
28/82
- 25 -
4 4.3.3(a)
Tissue611 14Spinal spheres, myospheres, 612 4
procured from BM.
Fig. 5
Tissue(b)
spinal cord Tissue29
Tissue
muscle Tissue30(c)
Tissue
lung Tissue31(d)
Tissue
Tissue Fig. 5(e)
32 Tissue Fig. 5
Tissue
Tissue
Tissue
c. 68 4 4.3.4 6 4Tissue generated
from spinalspheres 10 1duct like tissue endoderm)
29 Fig. 5 A30 Fig. 5 C31 Fig. 5 B32 Tissue Fig.4
Map2MyoD
7/24/2019 140717 Committee Report
29/82
- 26 -
Fig. 18).
(a)
Fig. 18
Tissue 613 4 2Tissue generated from
spinal spheres 9 5duct-like tissue (endoderm; Fig.
6Cv, Cvi).
Fig. 6 Ai B Aii C
Tissue(b)
Tissue Fig. 6 Ai
B Aii 14
Fig. 18
7
Tissue
Tissue
Tissue
d.
74 Fig. 18
4 4.3.4 6 4Tissue(a)
generated from spinalspheres 8 2duct like cuboidal
epithelium (endoderm) (Fig.18). 8 3Tissue
generated from myospheres 10 1duct like tissue
(endoderm) (Fig. 18).
Tissue 613 4 2
Tissue generated from spinal spheres 6 6
duct-like tissue (endoderm; Fig. 6Bv, Bvi). 6 7
Tissue generated from myospheres 9 5duct-like
7/24/2019 140717 Committee Report
30/82
- 27 -
tissue (endoderm; Fig. 6Cv, Cvi).
Fig. 6 Ai
B Aii C Tissue(b)
Tissue
Tissue
Tissue
Tissue
Tissue
e.
75
Fig. 19
4 4.3.4 10 2Tissue(a)
generated from pneumospheres 11 7cartilage
(mesoderm) (Fig.19), gland (ectoderm) (Fig.19).
Tissue 613 9 6Tissue generated from
pneumospheres 1 3cartilage (mesoderm; Fig.
6Diii, Div), and gland (ectoderm; Fig. 6Dv, Dvi).
Fig. 6 Aiii D
Tissue(b)
Tissue
Tissue
Tissue
Tissue
Tissue
7/24/2019 140717 Committee Report
31/82
- 28 -
5)
33
a.
29 2 2.2.1 14C. Trituration using
thin-glass pipette
17
by mechanical stress.
3
A. Cell sorterB. Optimistic pressureC. Trituration
using thin-glass pipetteC. Trituration
using thin-glass pipette
pipetting
b.
81 5
5
34
c. Curriculum VitaePatent
"Patent""Haruko
Obokata, Charles A. Vacanti. Sub Population of Retained Embryonic Like Cells"
6)
33 34 5 CDB
7/24/2019 140717 Committee Report
32/82
- 29 -
2.
1)
35
2 5
a.
2 4
2 4Tissue
Tissue
Tissue
(a)
S(b)
35
7/24/2019 140717 Committee Report
33/82
- 30 -
36
21 22 (c)
37
2 4
b.
5
51)
Aggregation Method
Injection Method 382)
393)
40 4)
GFPImmunohistochemistry
41
Tissue
(a)
36
37 38 5 5.2.1 5.3.139 5 5.3.240 5 5.2.2 5.3.341 5 5.2.3 5.3.3
7/24/2019 140717 Committee Report
34/82
- 31 -
Aggregation Method Injection Method
CDB U
Black6-GFP
22 8 9
10
U
2 22
8 910
8
105 20
22 8 9 10
22 8 9 10 U
(b)
22 8 9 10
22 12 CDB
22 12 21
GFP
U 22 12
U
(c)
22 9 9 11
17
7/24/2019 140717 Committee Report
35/82
- 32 -
GFP
U 22 9 9 11
17
22 10 14
GFP
GFP(d)
Immunohistochemistry
U 22 12 2GFP
GFP
Fig. 26
c.
2 4
Tissue TissueS
5
UU
2) Tissue
a.
TissueSYRQ T
SYRQ
T
7/24/2019 140717 Committee Report
36/82
- 33 -
SSYRQ
TTissue
Tissue
Tissue
b.
Tissue
Tissue
TissueTissue
5
22
422()
22
Curriculum
VitaeOriginal Papers Tissue
Tissue
Tissue Tissue
43
42 43 S
7/24/2019 140717 Committee Report
37/82
- 34 -
Tissue
3)
a.
26 5
28
b.
(a)
13
44
2 5(b)
5
(c)
44
4500
32
1
2 3
7/24/2019 140717 Committee Report
38/82
- 35 -
Fig. 7(d)
Fig. 10(e)
Figure(f)
2 Fig. 18 Fig. 19
Figure 3 Fig. 16Fig. 17
Fig. 18
c.
23 1 7(a)
3 Figure
45
i. 23 1 7
23
1 11
ii. 23 1 11
R
iii.
4647 48
3
3
45
7/24/2019 140717 Committee Report
39/82
- 36 -
3
3 2 FigureFig. 18Fig. 19
1
FigureFig. 16Fig. 17 Fig. 18
3
46
iv.
4647 48
v.
R
4647 48
3 Figure
(b)
.2.(3)c.(a)
3 Figure
2 Figure
46 46 Fig. 18
Fig. 18 47
Fig. 17 48
Fig. 19 Fig. 16
7/24/2019 140717 Committee Report
40/82
- 37 -
.2.(3)c.(a)iii.Fig. 16Fig. 17 Fig. 18
Figure 3
Figure 2
(c)
47
i. 22 11 13 1
22 11
13
1
4 5
2
ii.
2
Fig. 18 Fig. 19
iii. 23 1 11
Fig. 17
iv.
v.
22 11
47
7/24/2019 140717 Committee Report
41/82
- 38 -
.2.(3)c.(a)(b)
d.
.2.(3)c.
first author(a)
Tissue Tissue
Tissue
.1.
(b)
.1.(c)
(d)
Fig. 6Fig.
12 IFig. 17
(e)
U
7/24/2019 140717 Committee Report
42/82
- 39 -
e.
(a)
26 4 30
5 27
1
Nature
2
1
optimistic pressure(b)
optimistic pressureosmotic
pressure
48
48 P
7/24/2019 140717 Committee Report
43/82
- 40 -
optimistic
pressureosmotic pressure
1(c)
2 5
5
5
f.
7/24/2019 140717 Committee Report
44/82
- 41 -
49
(a)
i.
ii.
iii.
3 48 57
3 38
58 62
iv.
49
26 6 24
7/24/2019 140717 Committee Report
45/82
- 42 -
(b)
i.
Fig. 11
Fig. 12
Fig. 14Fig. 11
1214
ii. 3 3.3.1 1When
representative bone marrow derived 4 5
MyoD(mesoderm) and alpha-fetoprotein (AFP, endoderm) (Fig. 10).
Map2MyoD AFP
Tissue
7/24/2019 140717 Committee Report
46/82
- 43 -
611 4When representative BM-derived 8 1
MyoD (mesoderm), and AFP(endoderm).
Tissue
Tissue Fig. 4 A
Tissue Fig. 4 A
iii.
Tissue Fig. 4
A
iv.
3
NeuronMuscleHepatocyte
g.
.2.(3)f.
.1.
50
.1.
50 .1.
7/24/2019 140717 Committee Report
47/82
- 44 -
.2.
.2.(3)e.
1 2 3
1 2
3
1
2 3
h.
.2.(3)f.
.1.
i.
.2.(3)f.
7/24/2019 140717 Committee Report
48/82
- 45 -
.
4)
a.
41
Fig. 6
Fig. 6 2 2.3.4 2
Tissue 609
25 6Spheres of up to 150 m 39five generations
in this experiment.
Fig. 1
TissueFig. 6 Tissue
Fig. 1
Fig. 6(A)(B)(D)(J) Tissue Fig.
1(A)(B)(D)(J)
51Tissue
51 26 5 28
7/24/2019 140717 Committee Report
49/82
- 46 -
b.
43 Fig. 8 72 Fig. 16
TissueTissue
T
TTissue
TissueRetraction
TissueTissue
Tissue
Fig. 8 Fig. 16
7/24/2019 140717 Committee Report
50/82
- 47 -
II.
1.
Tissue
.3.(5)
2.
1) 23 1
.1.
23 1
2) 23 1
7/24/2019 140717 Committee Report
51/82
- 48 -
23 1
3)
1
)
a.
23 1
52
5354
5556
b.
(a)
52
23 1
53 454
255 569 2 3
4344355 174 2
56
7/24/2019 140717 Committee Report
52/82
- 49 -
57
(b)
Tissue
58
c.
.2.(3)a.
59
d.
.2.(3)
57
58 59
6 174
42 11
8 21 9 1197 18 1 2
7/24/2019 140717 Committee Report
53/82
- 50 -
.2.(3)b.
.2.(3)b.
1
2 3
1 2 3
4)
2
)
a.
23 1
60
61
b.
.2.(3)
(a)
60 189
310
11461
7/24/2019 140717 Committee Report
54/82
- 51 -
i.
22
2()
22
ii.
iii.
iv.
62
v.
(b)
i.
62
3
7/24/2019 140717 Committee Report
55/82
- 52 -
ii.
iii.
iv.
v. 22
(c)
i.
ii.
iii.
.1.
c.
.2.(4)b..2.(3)
7/24/2019 140717 Committee Report
56/82
- 53 -
(a)
.1.
1
4500
1 80 20 80
1
63
.2.(4)b.
(b)
.1.
1
1
1
.2.(4)b.
63
7/24/2019 140717 Committee Report
57/82
- 54 -
1(c)
.1. 1
1 1 1
1
1
1
.2.(4)b. 1
1
2(d)
.1. 2
2
.2.(4)b. 2
2
3(e)
.1. 3
3
.2.(4)b. 3
3
7/24/2019 140717 Committee Report
58/82
- 55 -
(f)
.1.
.2.(4)b.
3.
11
1 2 3
23 1
7/24/2019 140717 Committee Report
59/82
- 56 -
V.
1.
1)
7 2
19 2
1
3
2)
10
2
64 1
2
2.
.1.
64 22 6
21 4 8
7/24/2019 140717 Committee Report
60/82
- 57 -
3 1
3.
1)
a.
65
3 16(a)
18 1(b)
65 .3.(1)a.(m).3.(1)a.(n)
7/24/2019 140717 Committee Report
61/82
- 58 -
18
4Q R
18 4(c)
20 3
1
66Q
R
20 5R S(d)
S
20 9 21 3(e)
6 21 4 1 21 8
5
T S
(f)
21 8
21 8
66
7/24/2019 140717 Committee Report
62/82
- 59 -
21 8(g)
23 3
67
U
1
QR U
22 10(h)
22 11 11
22 11(i)
22 11 13(j)
(k)
1
67 22 43
7/24/2019 140717 Committee Report
63/82
- 60 -
(l)
4
23 1 7(m)
68
22 11(n)
23 1 7
221569(o)
.1.(p)
1 2 3
b.
.3.(1)a.
(a)
68 1
5
69 20 28 21 21 23
18 24 22 25 28
7/24/2019 140717 Committee Report
64/82
- 61 -
22 1123 1 7
.1.
(b)
.1.
(c)
.1.
7/24/2019 140717 Committee Report
65/82
- 62 -
70
(d)
.3.(1)b.
71
2)
.1.
a.
.3.(1)a..3.(1)b.
72
70
71
72 22 6
20 13 21 9 23 7 24 7
25 10 1
7/24/2019 140717 Committee Report
66/82
- 63 -
22 6 22 6
2
b.
.3.(1)a..3.(1)b.
73
74
4.
73
74
2
7/24/2019 140717 Committee Report
67/82
- 64 -
.
1.
1)
5 2
2
14 1
4
15
3 22
2()
22
2)
3
12 1
12 2 3
3 1
12 4
3)
22
22
a.
7/24/2019 140717 Committee Report
68/82
- 65 -
b.
c.
75
d.
e.
3 2
3 2
f.
75
7/24/2019 140717 Committee Report
69/82
- 66 -
2.
1)
.1.(2)
3 1
2)
3 1
76
3)
a.
76
644
7/24/2019 140717 Committee Report
70/82
- 67 -
3 1
b.
(a)
30 1
(b)
(c)
(d)
15
(e)
(f)
7/24/2019 140717 Committee Report
71/82
- 68 -
4)
a.
3 1
b.
(a)
11
(b)
(c)
(d)
(e)
7/24/2019 140717 Committee Report
72/82
- 69 -
3.
1)
a.
77
23 1 7(a)
78
R(b)
23 1 25
23 2 3
23 2 9(c)
23 2 9(d)
77 IV.3.(1)a.(a)
78 1
5
7/24/2019 140717 Committee Report
73/82
- 70 -
(e)
(f)
.1.(g)
1 2 3
b.
.2.(1)
(a)
.1.
(b)
7/24/2019 140717 Committee Report
74/82
- 71 -
(c)
(d)
.3.(1) b.
79
2)
a.
23 1 7(a)
R(b)
79
.3.(1)
7/24/2019 140717 Committee Report
75/82
- 72 -
23 1 25
23 2 3
23 2 9(c)
23 2 9(d)
(e)
(f)
.1.(g)
1 2 3
b.
.2.(2)
(a)
7/24/2019 140717 Committee Report
76/82
- 73 -
.1.
(b)
(c)
(d)
80
3)
.2.(3)b.
80
7/24/2019 140717 Committee Report
77/82
- 74 -
.1.
4)
.2.(4)b.
5)
.1.
a.
7/24/2019 140717 Committee Report
78/82
- 75 -
b.
.1.
81
82
81
82
7/24/2019 140717 Committee Report
79/82
- 76 -
c.
.1.
d.
.1.
22
83
e.
83
7/24/2019 140717 Committee Report
80/82
- 77 -
4.
.1.
7/24/2019 140717 Committee Report
81/82
- 78 -
I.
Tissue
2
1
2
7/24/2019 140717 Committee Report
82/82